



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application of:

Confirmation No. 5890

Jeffrey SCHLOM *et al.*

Application No.: 10/725,373

Art Unit: 1644

Filed: December 3, 2003

Examiner: DiBrino, M.

For: AGONIST AND ANTAGONIST PEPTIDES OF CARCINOEMBRYONIC ANTIGEN
(CEA)

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A are documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

10/13/2005 JADD01 00000081 10725373

02 FC:1806 180.00 DA

A copy of the European search report setting forth the portion of each reference considered relevant by the examiner is attached.

Documents B01-B05 were cited by Applicants in a previously filed Information Disclosure Statement on August 3, 2003, at which time copies of the references were provided. Therefore, Applicants are not enclosing copies at this time.

TIMING/FEE


The instant Information Disclosure Statement is being filed after the mailing of a first Office action on the merits but before the mailing date of either (1) a final action under §1.113; (2) a notice of allowance under §1.311; or (3) an action that otherwise closes prosecution in the application. The required fee in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached. The Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Date: OCTOBER 12 2005

Heller Ehrman LLP
1717 Rhode Island Avenue, NW
Washington, D.C. 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020


Respectfully submitted,



Ronald J. Kamis
Reg. No. 41,104
Attorney for Applicant

Customer No. 44991

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/725,373
		Filing Date	December 3, 2003
		First Named Inventor	Jeffrey SCHLOM et al.
		Group Art Unit	1644
		Examiner Name	Marianne Nmn Dibrino
Sheet 2 of 2	Attorney Docket Number	38163-0197	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B02	CHEN, Y., et al., Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: characterization and frequencies of TCR agonist and TCR antagonism with or without partial activation. J. Immunol., 157: 3783-3790 (1996).	
	B03	JAMESON, S.C., et al., T cell receptor antagonists and partial agonists. Immunity, 2:1-11 (1995).	
	B04	TSANG, K.Y., et al., Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87:982-990 (1995).	
	B05	ZAREMBA, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Research. 57:4570-4577 (1997).	
	B06	RUPPERT J. et al., "Class I MHC-Peptide Interaction: Structural and Functional Aspects", Behring Institute: Mitteilungen, July 1, 1994, p. 48-60, no. 94, XP000604845	
	B07	DENIS HUDRISIER et al., "Binding of Viral Antigens to Major Histocompatibility Complex Class I H-2D ^b Molecules Is Controlled by Dominant Negative Elements at Peptide Non-anchor Residues", The Journal of Biological Chemistry", 1996, pp. 17829-17836, Vol. 271, No. 30	
	A08	LUIS JAVIER SIGAL et al., "Role of Non-Anchor Residues of D ^b -Restricted Peptides in Class I Binding and TCR Triggering", Molecular Immunology, 1996, pp. 1323-1333, Vol. 33, No. 17/18	
	A09	LUIS J. SIGAL et al., "D ^b -Binding Peptides from Influenza Virus: Effect of Non-Anchor Residues on Stability and Immunodominance", Molecular Immunology, 1995, pp. 623-632, Vol. 32, No. 9	
	A10	CATARINA E. HIOE et al., "Alterations of a Dominant Epitope of Lymphocytic Choriomeningitis Virus Which Affect Class I Binding and Cytotoxic T Cell Recognition", Molecular Immunology, 1995, pp. 725-731, Vol. 32, No. 10	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.